The product information on this website, which will be updated periodically, is intended solely for use by healthcare professionals. A healthcare professional must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. These products may not be approved and/or licensed in all countries and/or regions where this website is accessible. Zai Lab has certain rights to develop and commercialize these products pursuant to license arrangements. Trademarks appearing on this webpage are the property of their respective owner.
Zejula®
Niraparib
ZEJULA (niraparib) is an orally administered poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor. PARP is a protein that helps repair DNA damage in cells. PARP inhibitors block PARP from repairing DNA damage, such as may be caused by radiation and/or certain chemotherapies. This inhibition of DNA damage repair can lead to cancer cell death and slow the return or progression of cancer.
Zai Lab currently sells ZEJULA in mainland China, Hong Kong and Macau as a first-line maintenance treatment for ovarian cancer and a maintenance treatment for platinum-sensitive relapsed ovarian cancer.
For inquiries about ZEJULA in Greater China*, please email medinfo@zailaboratory.com.
OPTUNE GIO ™ and OPTUNE LUA®
Tumor Treating Fields
Tumor Treating Fields (TTFields) is a cancer therapy that uses electric fields tuned to selectively target and kill tumor cells via a variety of mechanisms, including disruption of mitosis, downregulation of DNA damage response, downstream enhancement of anti-tumor immunity, and interference of cell movement and migration. TTFields therapy is delivered through a portable medical device. The complete delivery system includes a portable electric field generator, arrays, rechargeable batteries and accessories. Sterile, single-use arrays are placed directly on the skin in the region surrounding the tumor and connected to the electric field generator to deliver therapy.
TTFields devices are marketed under various brand names, including OPTUNE GIO® for glioblastoma multiforme (GBM), an aggressive form of brain tumor, and OPTUNE LUA® for malignant pleural mesothelioma (MPM), a type of cancer that occurs in the thin layer of tissue in the torso covering internal organs.
Zai Lab currently sells OPTUNE GIO in Greater China* for the treatment of patients with newly diagnosed and recurrent GBM.
Zai Lab currently sells OPTUNE LUA in Hong Kong and Macau for the treatment of unresectable, locally advanced or metastatic MPM.
For inquiries about TTFields in Greater China*, please email medinfo@zailaboratory.com.
QINLOCK®
Ripretinib
QINLOCK (ripretinib) is an orally administered switch-control tyrosine kinase inhibitor (TKI) that inhibits KIT and PDGFRA kinases, including wild-type and forms with multiple primary and secondary mutations, by using a dual mechanism of action that regulates the kinase switch pocket and activation loop.
Zai Lab currently sells QINLOCK in Greater China* for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib.
For inquiries about QINLOCK in Greater China*, please email medinfo@zailaboratory.com.
AUGTYRO™
Repotrectinib
AUGTYRO (repotrectinib) is a next-generation tyrosine kinase inhibitor (TKI) of proto-oncogene tyrosine-protein kinase ROS1 and of the tropomyosin receptor tyrosine kinases (TRKs) TRKA, TRKB, and TRKC. Patients with solid tumors harboring ROS1 and NTRK gene fusions treated with other currently approved therapies often develop resistance mutations that limit their efficacy and result in tumor progression.
AUGTYRO has been approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in mainland China and Macau.
For inquiries about AUGTYRO in Greater China*, please email medinfo@zailaboratory.com.
NUZYRA®
Omadacycline
NUZYRA (omadacycline), a novel tetracycline-class antibacterial with both oral and IV formulations that is a broad-spectrum antibiotic.
Zai Lab currently sells NUZYRA in mainland China for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
For inquiries about NUZYRA in Greater China*, please email medinfo@zailaboratory.com.
XACDURO®
Sulbactam-durlobactam
XACDURO (sulbactam-durlobactam (SUL-DUR)) is an intravenously administered drug that is a combination of sulbactam (a β-lactam antibiotic) and durlobactam (a broad-spectrum β-lactamase inhibitor).
XACDURO has been approved in mainland China for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (ABC) in patients 18 years of age and older.
For inquiries about XACDURO in Greater China*, please email medinfo@zailaboratory.com.
Efgartigimod
Efgartigimod alfa-fcab (or efgartigimod alfa or efgartigimod) is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn). It has the potential to address a multitude of severe autoimmune diseases where pathogenic IgGs are believed to be mediators of disease and is being evaluated in several autoimmune indications.
Efgartigimod is available as VYVGART® intravenous formulation and as a subcutaneous formulation (Efgartigimod SC). Efgartigimod SC uses recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE® drug delivery technology, to facilitate subcutaneous delivery.
Zai Lab currently sells VYVGART® intravenous formulation in mainland China as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. Efgartigimod SC has been approved in mainland China for this indication.
For inquiries about VYVGART and Efgartigimod SC in Greater China*, please email medinfo@zailaboratory.com.
* Greater China = mainland China, Hong Kong, Macau and Taiwan, collectively.